Why D-Wave Quantum Stock Keeps Going Up

The U.S. Department of Commerce confirmed $100 million in grant funding for D-Wave Quantum under the CHIPS and Science Act to improve qubit counts and error rates. The award is meaningful but limited relative to D-Wave's cash burn, which exceeded $100 million over the last 12 months, implying roughly one additional year of runway. D-Wave shares have already surged 66% in three trading days on the news, but the company remains a risky, pre-profit quantum computing bet.

Analysis

The market is likely pricing the grant as quasi-survival capital, but the more important signal is political validation: once a company is selected into a federally sponsored quantum stack, its fundraising optionality improves faster than its operating metrics. That tends to widen the gap between narrative winners and economically stronger peers, especially in a pre-revenue sector where “strategic relevance” can overpower near-term cash burn concerns for several quarters.

The second-order effect is more interesting for IBM and GFS than for QBTS. IBM’s exposure is less about a direct balance-sheet uplift and more about becoming the default institutional proxy for government-grade quantum infrastructure, which can attract a durability premium even if the dollar amount is modest relative to its scale. GFS may benefit from being viewed as a key manufacturing enabler for the broader quantum ecosystem, but that upside is likely slower and more diffuse; any multiple expansion should be capped unless the grant program translates into follow-on fabrication contracts.

For QBTS, the rally risks outrunning the fundamental bridge. A $100 million award extends runway, but it does not solve the core issue: the company still needs either faster commercialization or repeated external funding to avoid dilution and/or financing overhang within 6-12 months. In this type of tape, the first reversal catalyst is usually not bad news but the absence of follow-through: when traders realize the announcement is non-dilutive only in the short term, momentum can fade sharply after the initial squeeze.

The contrarian read is that this may be a better event for selling volatility than chasing spot. The move likely overshoots because the stock is being traded as a policy lottery ticket rather than a cash-flow asset, and those setups often mean-revert once the market shifts from headline to execution. The base case remains that quantum remains years away from material economics, so the near-term trade is more about positioning and flow than intrinsic value.

Key Decisions for Investors

• Fade strength in QBTS with a short into post-news momentum exhaustion over the next 1-3 weeks; risk/reward favors mean reversion if the stock fails to hold recent gap gains.
• Buy QBTS put spreads 1-3 months out rather than outright short stock, to express downside on delayed commercialization/dilution risk while limiting squeeze exposure.
• Long IBM / short QBTS as a relative-value pair for 1-2 quarters: IBM captures the institutional-policy premium, while QBTS carries the highest execution and financing risk.
• Add GFS only on pullbacks, not breakouts; treat it as a slower-moving beneficiary of ecosystem spend with limited immediate catalyst sensitivity.
• If already long QBTS, take partial profits into the first 2-3 days of momentum and keep a hard stop below the post-announcement breakout level, since the trade is flow-driven and can reverse quickly.